JP2023052258A5 - - Google Patents

Download PDF

Info

Publication number
JP2023052258A5
JP2023052258A5 JP2023001177A JP2023001177A JP2023052258A5 JP 2023052258 A5 JP2023052258 A5 JP 2023052258A5 JP 2023001177 A JP2023001177 A JP 2023001177A JP 2023001177 A JP2023001177 A JP 2023001177A JP 2023052258 A5 JP2023052258 A5 JP 2023052258A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
fusion protein
disease
group
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023001177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023052258A (ja
JP7456024B2 (ja
Filing date
Publication date
Priority claimed from JP2020209139A external-priority patent/JP7208963B2/ja
Application filed filed Critical
Publication of JP2023052258A publication Critical patent/JP2023052258A/ja
Publication of JP2023052258A5 publication Critical patent/JP2023052258A5/ja
Application granted granted Critical
Publication of JP7456024B2 publication Critical patent/JP7456024B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023001177A 2015-01-12 2023-01-06 Il-17a結合ポリペプチド Active JP7456024B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15150786 2015-01-12
EP15150786.0 2015-01-12
JP2020209139A JP7208963B2 (ja) 2015-01-12 2020-12-17 Il-17a結合ポリペプチド

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020209139A Division JP7208963B2 (ja) 2015-01-12 2020-12-17 Il-17a結合ポリペプチド

Publications (3)

Publication Number Publication Date
JP2023052258A JP2023052258A (ja) 2023-04-11
JP2023052258A5 true JP2023052258A5 (cg-RX-API-DMAC10.html) 2023-07-19
JP7456024B2 JP7456024B2 (ja) 2024-03-26

Family

ID=52339024

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017535976A Active JP6943764B2 (ja) 2015-01-12 2016-01-12 Il−17a結合ポリペプチド
JP2020209139A Active JP7208963B2 (ja) 2015-01-12 2020-12-17 Il-17a結合ポリペプチド
JP2023001177A Active JP7456024B2 (ja) 2015-01-12 2023-01-06 Il-17a結合ポリペプチド

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2017535976A Active JP6943764B2 (ja) 2015-01-12 2016-01-12 Il−17a結合ポリペプチド
JP2020209139A Active JP7208963B2 (ja) 2015-01-12 2020-12-17 Il-17a結合ポリペプチド

Country Status (19)

Country Link
US (3) US10934335B2 (cg-RX-API-DMAC10.html)
EP (3) EP3245224B1 (cg-RX-API-DMAC10.html)
JP (3) JP6943764B2 (cg-RX-API-DMAC10.html)
KR (2) KR20240110106A (cg-RX-API-DMAC10.html)
CN (1) CN108064235A (cg-RX-API-DMAC10.html)
AU (1) AU2016208161B2 (cg-RX-API-DMAC10.html)
CA (1) CA2972683A1 (cg-RX-API-DMAC10.html)
DK (1) DK3245224T3 (cg-RX-API-DMAC10.html)
ES (1) ES2822431T3 (cg-RX-API-DMAC10.html)
HU (1) HUE052121T2 (cg-RX-API-DMAC10.html)
IL (1) IL253004B (cg-RX-API-DMAC10.html)
MX (1) MX394167B (cg-RX-API-DMAC10.html)
MY (1) MY188784A (cg-RX-API-DMAC10.html)
NZ (1) NZ732978A (cg-RX-API-DMAC10.html)
PL (1) PL3245224T3 (cg-RX-API-DMAC10.html)
PT (1) PT3245224T (cg-RX-API-DMAC10.html)
RU (1) RU2749712C2 (cg-RX-API-DMAC10.html)
WO (1) WO2016113246A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201704366B (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
CN108949789A (zh) * 2018-06-26 2018-12-07 山东兴瑞生物科技有限公司 抗gcc的核酸、其制备方法、具有该核酸的免疫细胞及其应用
JP7525499B2 (ja) * 2019-01-31 2024-07-30 ヌマブ セラピューティクス アクチェンゲゼルシャフト TNFα及びIL-17Aに対する特異性を有する多重特異性抗体、IL-17Aを標的とする抗体、及びそれらの使用方法
WO2021089695A1 (en) * 2019-11-05 2021-05-14 Affibody Ab Polypeptides
CN111856029B (zh) * 2020-06-19 2023-09-26 北华大学 Il-17a蛋白在膀胱癌中的应用
MX2024009732A (es) * 2022-02-08 2024-08-19 Affibody Ab Variantes de la proteina z que enlazan la linfopoyetina estromal timica y su uso medico.
US20260028397A1 (en) 2022-04-07 2026-01-29 Acelyrin, Inc. Methods of treating ankylosing spondylitis
WO2023196916A1 (en) * 2022-04-07 2023-10-12 Acelyrin, Inc. Methods of treating of hidradenitis suppurativa
EP4704911A1 (en) * 2023-05-04 2026-03-11 Affibody AB New polypeptide
CN116466095B (zh) * 2023-06-15 2023-09-01 朗肽生物制药股份有限公司 一种多肽及其应用
EP4773985A1 (en) * 2023-09-08 2026-07-15 Affibody AB Methods of treating hidradenitis suppurativa

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0524788D0 (en) 2005-12-05 2006-01-11 Affibody Ab Polypeptides
PL1963368T6 (pl) 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
JP2010515463A (ja) 2007-01-12 2010-05-13 シー レーン バイオテクノロジーズ, エルエルシー 配座的に束縛されたポリペプチド配列のコンビナトリアルライブラリー
DE08786222T1 (de) 2007-07-31 2010-11-25 Affibody Ab Neue albuminbindende zusammensetzungen, verfahren und anwendungen
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
NZ594514A (en) * 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
CA2772162C (en) * 2009-08-27 2018-05-22 Covagen Ag Anti-il-17a fynomers and medical uses thereof
WO2011110515A1 (en) * 2010-03-08 2011-09-15 Affibody Ab Immunoglobulin g fc region binding polypeptide
BR112013000452A2 (pt) 2010-07-09 2020-02-11 Affibody Ab Polipeptídeo de ligação de albumina, proteína de fusão ou conjugado, polinucleotídeo, método para produzir um polipeptídeo, composição, método para a preparação de uma composição, e, método para aumentar a solubilidade de um composto
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
EP2597102A1 (en) * 2011-11-25 2013-05-29 Covagen AG A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17
KR102149028B1 (ko) * 2012-02-20 2020-08-27 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 폴리펩티드
EP2711016A1 (en) * 2012-09-21 2014-03-26 Covagen AG Novel IL-17A binding molecules and medical uses thereof
US10155792B2 (en) 2012-09-25 2018-12-18 Affibody Ab Albumin binding polypeptide
PL2912054T3 (pl) 2012-10-25 2017-11-30 Affibody Ab Polipeptyd wiążący albuminę
WO2014113804A1 (en) * 2013-01-21 2014-07-24 Abbvie Inc. Anti-tnf and anti-il17 combination therapy biomarkers for inflammatory disease
MX366425B (es) * 2013-03-15 2019-07-04 Affibody Ab Nuevos polipeptidos.
WO2015091957A1 (en) 2013-12-20 2015-06-25 Affibody Ab Engineered albumin binding polypeptide

Similar Documents

Publication Publication Date Title
JP2021073174A5 (cg-RX-API-DMAC10.html)
JP5667171B2 (ja) 二機能性ポリペプチド
JP2023076828A5 (cg-RX-API-DMAC10.html)
JP2022502056A5 (cg-RX-API-DMAC10.html)
IL308851B2 (en) T-cell modulatory multimeric polypeptides and methods of use thereof
JP2025138715A5 (cg-RX-API-DMAC10.html)
AU2020380296A1 (en) IL-2RβγC binding compounds
ES2199941T3 (es) Anticuerpos monoclonales contra el receptor de la interferona, con actividad neutralizadora contra el interferon de tipo j.
JP2012530145A5 (cg-RX-API-DMAC10.html)
JP2018509935A5 (cg-RX-API-DMAC10.html)
JP2013513377A5 (cg-RX-API-DMAC10.html)
JP2014224121A5 (cg-RX-API-DMAC10.html)
JP2019516665A5 (cg-RX-API-DMAC10.html)
JP2008504012A5 (cg-RX-API-DMAC10.html)
JPH04500357A (ja) 心房の,ナトリウム排出亢進性ペプチドの環式アナログ
JP2018506287A5 (cg-RX-API-DMAC10.html)
JP2002514418A5 (cg-RX-API-DMAC10.html)
JP2019530441A5 (cg-RX-API-DMAC10.html)
JP2021531834A5 (cg-RX-API-DMAC10.html)
RU2017127012A (ru) IL-17A-связанные полипептиды
JP2024543204A5 (cg-RX-API-DMAC10.html)
JP2024524534A5 (cg-RX-API-DMAC10.html)
JP2022514348A5 (cg-RX-API-DMAC10.html)
JP2024521092A5 (cg-RX-API-DMAC10.html)
KR970070198A (ko) 항-파스 재조합 항체 및 이에 대한 디엔아이